Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove energy prices up and created cautious global markets. Energy, Basic Materials, and Industrials performed well, while software companies faced challenges due to AI disruption concerns. Market sensitivity to geopolitical events, energy prices, and inflation remains high. The Conestoga Small Cap Composite fell 5.01%, underperforming the Russell 2000 Growth’s -2.81% return. The decline was driven by negative stock selection and headwinds in Technology and Health Care, with sector allocation benefits insufficient to offset losses. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Conestoga Capital Advisors highlighted Artivion, Inc. (NYSE:AORT) as a newly added position. Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues. On April 27, 2026, Artivion, Inc. (NYSE:AORT) closed at $37.03 per share. One-month return of Artivion, Inc. (NYSE:AORT) was 1.12%, and its shares gained 54.36% over the past 52 weeks. Artivion, Inc. (NYSE:AORT) has a market capitalization of $1.8 billion.
Conestoga Capital Advisors stated the following regarding Artivion, Inc. (NYSE:AORT) in its Q1 2026 investor letter:
“Artivion, Inc. (NYSE:AORT) develops, manufactures, and distributes specialized products used in cardiac and vascular surgery. Products include stent grafts, mechanical heart valves, surgical sealants, and tissues. The company continues to build momentum across its core product portfolio, supported by new product launches, strong clinical data, and PMA approvals. The business is increasingly focused on complex aortic repair, which we believe can drive consistent growth and margin improvement over time.”
Artivion, Inc. (NYSE:AORT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 25 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the fourth quarter, compared to 26 in the previous quarter. While we acknowledge the risk and potential of Artivion, Inc. (NYSE:AORT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Artivion, Inc. (NYSE:AORT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Artivion, Inc. (NYSE:AORT) and shared the list of best small-cap growth stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
